title: Peroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitary.
abstract: Pituitary adenomas are slow-growing tumours arising within the pituitary gland. If secreting, they give rise to well-known syndromes such as Cushing's disease or acromegaly; when hormonally inactive, they come to clinical attention often with local mass effects or pituitary deficiency. Peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear hormone receptor with a key role in fat and glucose metabolism, but also involved in several neoplasia, has recently been detected in pituitary adenomas. In the present study, we evaluated the occurrence and splicing profile of PPARgamma in 43 cases of pituitary adenoma of different subtypes and compared it to 12 normal pituitary glands. By real-time polymerase chain reaction, PPARgamma was expressed as much in adrenocorticotrophic hormone (ACTH)-secreting and ACTH-silent adenomas as in controls, with a moderate underexpression in somatotrophinomas and prolactinomas and overexpression in 54% of nonfunctioning pituitary adenomas (NFPA). There was no apparent qualitative change in the splicing profile of pathological pituitary glands, nor was the presence of specific isoforms with dominant negative effects against PPARgamma detected. Western blotting revealed similar expression levels in the different subgroups of pituitary adenomas and normal glands. Immunohistochemistry confirmed PPARgamma expression in approximately one-half of analysed samples. The intra- and intergroup differences observed in pituitary adenomas may represent new elements in the process of understanding the different clinical responses of Cushing's and Nelson patients to PPARgamma-ligand treatment. Moreover, the higher level of PPARgamma expression detected in the NFPA subgroup may suggest its possible role as a molecular target in these pituitary adenomas, paving the way for investigations on the effectiveness of treatment with thiazolidinediones in such patients.
authors.affiliation: Division of Endocrinology, Department of Medical and Surgical Sciences, University of Padova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Occhi
authors.forename: N
authors.initials: N
authors.lastname: Albiger
authors.forename: S
authors.initials: S
authors.lastname: Berlucchi
authors.forename: M
authors.initials: M
authors.lastname: Gardiman
authors.forename: M
authors.initials: M
authors.lastname: Scanarini
authors.forename: R
authors.initials: R
authors.lastname: Scienza
authors.forename: A
authors.initials: A
authors.lastname: Fassina
authors.forename: F
authors.initials: F
authors.lastname: Mantero
authors.forename: C
authors.initials: C
authors.lastname: Scaroni
mesh_terms: D000236:Adenoma / Q000378:metabolism*; D001483:Base Sequence; D017931:DNA Primers; D006801:Humans; D007150:Immunohistochemistry; D047495:PPAR gamma / Q000378:metabolism*; D010902:Pituitary Gland / Q000378:metabolism*; D010911:Pituitary Neoplasms / Q000378:metabolism*; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D017931:DNA Primers; D047495:PPAR gamma; D012333:RNA, Messenger